[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early-stage non-small cel...
Source: Roche Investor Update - April 25, 2022 Category: Pharmaceuticals Source Type: news
Zanubrutinib Shows Worth Against Standard CLL Drugs Zanubrutinib Shows Worth Against Standard CLL Drugs
Patients with chronic lymphocytic leukemia could soon be offered a novel treatment option after trial data showed zanubrutinib improves outcomes against standard therapies.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Some Leukemias Detectable Up to 16 Years Before Diagnosis? Some Leukemias Detectable Up to 16 Years Before Diagnosis?
The preclinical phase of chronic lymphocytic leukemia may be exist longer than previously thought, suggests a sequencing analysis of blood samples obtained up to 22 years prior to diagnosis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 8, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Mayo Clinic discovery in bone marrow cancer points to potential drug targets
ROCHESTER, Minn. — New research from Mayo Clinic's Center for Individualized Medicine finds that patients with ASXL1-mutant chronic myelomonocytic leukemia — an uncommon type of cancer of the bone marrow — have distinctive epigenetic changes that can activate harmful genes and cause the cancer to grow faster. The ASXL1 genetic mutation also can transform the disease into the more aggressive acute myeloid leukemia. The study, published in Nature Communications, helps to clarify a potential therapeutic… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 17, 2022 Category: Databases & Libraries Source Type: news
Janssen Seeks Approval of a New Indication for IMBRUVICA ® (ibrutinib) for Use in Patients with Untreated Mantle Cell Lymphoma
BEERSE, BELGIUM, 8 March 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval of a new indication for IMBRUVICA® (ibrutinib) in combination with bendamustine and rituximab (BR) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for autologous stem cell transplantation (ASCT).Ibrutinib is a once-daily Bruton's tyrosine kinase (BTK) inhibitor that is currently approved for patients with MCL who have received at least one prior lin...
Source: Johnson and Johnson - March 8, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Angola: President Unveils Pediatric Hematology Institute
[ANGOP] Luanda -- Angolan head of State Jo ão Lourenço inaugurated Friday in Luanda the Pediatric Hematology Institute, specialised in treatment of patients with sickle cell anemia, acute and chronic leukemia. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 5, 2022 Category: African Health Source Type: news
What Are Some Mast Cell Disorders?
Discussion
Mast cells (MCs) were first discovered by Paul Ehrlich in 1878. Previously in 1869, Nettleship and Tay described a toddler with chronic urticaria and a brown skin lesion which is believed to be the first reported case of mastocytosis. Urticaria pigmentosa was a term first used by Sangster in 1878, and in 1936 the term mastocytosis was used.
“Mast cells first evolved 500 million years ago in Ascidians (sea squirts), providing host innate immunity against bacteria and parasites….MCs gained additional functions regulating inflammation, wound healing, coagulation, adaptive immunity and acute allergic res...
Source: PediatricEducation.org - February 21, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Durable Remission Seen in Two CLL Patients After CAR T Cell Therapy
TUESDAY, Feb. 15, 2022 -- Long-term chimeric antigen receptor (CAR) T cell signaling and persistence has been demonstrated at more than 10 years after infusion in two chronic lymphocytic leukemia (CLL) patients, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 15, 2022 Category: Pharmaceuticals Source Type: news
Outlook on Chronic Lymphocytic Leukemia: How Clinical Trials Can Improve Patient Outcomes Outlook on Chronic Lymphocytic Leukemia: How Clinical Trials Can Improve Patient Outcomes
Deborah M. Stephens, DO, considers the role of clinical trials both in the development of more effective therapies and the often dramatically improved outcomes of their participants.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 11, 2022 Category: Consumer Health News Tags: None MDAngle Source Type: news
Outlook on Chronic Lymphocytic Leukemia: From Theory to Practice Outlook on Chronic Lymphocytic Leukemia: From Theory to Practice
Deborah M. Stephens, DO, reflects on how involvement in a mentor ' s clinic prompted her to focus on chronic lymphocytic leukemia.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 10, 2022 Category: Consumer Health News Tags: None MDAngle Source Type: news
Advice for Physicians Entering the Field of Chronic Lymphocytic Leukemia Advice for Physicians Entering the Field of Chronic Lymphocytic Leukemia
Bruce Cheson, MD, shares his enthusiasm about novel therapies in the management of chronic lymphocytic leukemia with practitioners who are entering the field.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 7, 2022 Category: Consumer Health News Tags: None MDAngle Source Type: news
CLL Patients'Cured': 10 Years Post-Infusion, CAR T Cells Persist CLL Patients'Cured': 10 Years Post-Infusion, CAR T Cells Persist
Two patients with chronic lymphocytic leukemia who were among the first to receive the groundbreaking therapy were still in remission a decade later.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 3, 2022 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter: United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major appro...
Source: Roche Investor Update - February 3, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals f...
Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news
Prognostic Index May ID CLL Patients Who Will Not Need Treatment
Novel prognostic index CLL - WONT identifies patients with chronic lymphocytic leukemia who are at low risk for ever requiring treatment (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 25, 2022 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news
